Pruritus Associated with Targeted Anticancer Therapies and Their Management

Targeted anticancer therapies have significantly increased the survival of patients with a variety of malignancies, improved the tolerability, and prolonged treatment duration. 1 The increased lifespan and the expanded use of these targeted agents have led to a variety of treatment-related adverse events. Pruritus is a common dermatologic adverse event with various incidences ranged from 2.2 to 47% across different categories of targeted anticancer therapies, yet has been overlooked in the past. In this article, we reviewed the incidence, accompanied skin conditions, possible pathomechanism and proposed management algorithms of pruritus associated with targeted therapies including immunotherapies.